Last Updated : July 24, 2024
Details
Generic Name:
liraglutide
Project Status:
Not filed
Therapeutic Area:
Diabetes Mellitus, Type 2 (pediatric)
Manufacturer:
Novo Nordisk Canada Inc.
Brand Name:
Victoza
Project Line:
Reimbursement Review
Project Number:
NS0032-000
Biosimilar:
No
Submission Type:
Non-submission
Fee Schedule:
N/A
Indications:
In adolescents and children aged 10 years and above with type 2 diabetes, Victoza is indicated as an adjunct to metformin with or without basal insulin, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control.
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : July 24, 2024